Embera NeuroTherapeutics, Inc., is a specialty biopharmaceutical company focused on developing treatments for smoking cessation, cocaine use disorder and other addictions, for which there are a limited range of effective drug therapies or no approved treatment options. Embera is developing a novel, patented drug combination (EMB-001) targeting specific brain functions related to stress response that drive craving and relapse associated with these disorders, an approach based on years of NIH-funded research on the role of stress in addiction and potential treatments. EMB-001 has been tested with promising clinical results in a published pilot study in cocaine-dependent human subjects.
In addition, potential efficacy for cocaine, nicotine and methamphetamine use disorders has been shown in published preclinical models of these addictions. Embera's preclinical study in nicotine dependence for EMB-001 demonstrated a statistically significant reduction in nicotine self-administration — up to 80% reduction, versus only a 50% reduction seen with varenicline (Chantix®).
Embera has completed work under a $3.9M grant by the National Institute on Drug Abuse (NIDA) to support EMB-001’s cocaine dependence development program through the EMB-001 investigational new drug (IND) application. Embera has initiated an EMB-001 Phase 1 safety and pharmacokinetic study in otherwise healthy smokers. This work enables and complements Embera's smoking cessation and cocaine dependence development programs.
Listen to the 2/18/14 episode of BioTech Nation
with host Dr. Moira Gunn. Robert Linke, Embera's CEO, discusses EMB-001 and smoking cessation. Availble via the following YouTube video.